BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Bioventus Inc.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$13.49+0.19 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $955.61M
- P/E (TTM)
- 17.5
- Dividend yield
- –
Share price
+$6.83 (+102.6%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Bioventus Inc. grew revenue 3.1% to $581.85M over the twelve months to Jun 27, 2026. Operating income rose 68.5% to $58.28M, moving the operating margin from 6.1% to 10.0%. Free cash flow was $94.29M, up 176.5% from a year earlier.
Revenue
$581.85M
+3.1% vs. a year earlier
Operating income
$58.28M
+68.5% vs. a year earlier
Free cash flow
$94.29M
+176.5% vs. a year earlier
EPS, diluted
$0.77
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 27, 2026
Valuation
- Market cap
- $955.61M
- P/E ratio
- 17.5
- Price to sales
- 1.64
- Price to book
- 4.19
- Dividend yield
- –
- Free cash flow yield
- 9.87%
Fundamentals
- Revenue
- $581.85M
- Net income
- $54.46M
- EPS, diluted
- $0.77
- Free cash flow
- $94.29M
- Book value per share
- $3.22
- Diluted shares
- 71M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$581.85M+3.1% YoY
Gross profit
$399.45M+4.7% YoY
Operating income
$58.28M+68.5% YoY
Net income
$54.46M
EPS, diluted
$0.77
Free cash flow
$94.29M+176.5% YoY
Reported periodTrailing twelve months